Please login to the form below

Not currently logged in
Email:
Password:

amyloid

This page shows the latest amyloid news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

There have been dozens of amyloid-targeting drug s that failed to meet the mark in testing, but researchers have plugged on in the hope that using them at ever-earlier ... BACE inhibitors are designed to block the formation of the amyloid plaques that

Latest news

  • Boehringer abandons PDE-targeted Alzheimer’s drug Boehringer abandons PDE-targeted Alzheimer’s drug

    Efforts to develop new therapies for Alzheimer’s have resulted in a litany of failures, many involving drugs targeting the beta amyloid pathway that leads to the formation of the characteristic ... An anti-amyloid drug developed by Boehringer and Eisai

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    Meanwhile, other diabetes drugs have also been tested for activity in AD, including Novo Nordisk's Victoza (liraglutide) which seemed to reduce amyloid plaque formation but had no effect on cognitive

  • Pfizer drops neuroscience R&D, cutting 300 jobs Pfizer drops neuroscience R&D, cutting 300 jobs

    Alzheimer’s in particular has been a barren wasteland for new drugs with dozens of candidates - many targeting beta amyloid including Pfizer’s own bapineuzumab candidate - failing to have an impact

  • Axovant joins ever-growing Alzheimer’s failure club Axovant joins ever-growing Alzheimer’s failure club

    While most drugs in development for Alzheimer's disease - and a good proportion of the failures - have targeted the amyloid beta protein found in the plaques seen in the brains of

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    Alnylam's success in the phase III trial proved to be a dampener for Ionis Pharmaceuticals, which is developing antisense-based drug inotersen for this type of familial amyloid polyneuropathy (FAP).

More from news
Approximately 12 fully matching, plus 116 partially matching documents found.

Latest Intelligence

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Examples of digital biomarker usage cases include:. Using an interactive app to pre-screen potential study participants; for instance, a game to assess cognitive ability as a predictor of beta-amyloid

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    All highly disappointing for Lilly (which saw its stock sink), for academics that backed the amyloid hypothesis and for patients. ... Professor Peter Roberts at the University of Bristol is one of those who feels that the amyloid card has been overplayed.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly's great hope in amyloid beta is now solanezumab, a candidate with a chequered history. ... I think Amyloid-beta will be a very powerful approach for early-stage disease, for delaying the onset of symptoms and their progression.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease. ... Alzheon's founder, president and chief executive officer Martin Tolar said: “ JP will provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics